Kukkar Deepak, Kukkar Preeti, Kumar Vanish, Hong Jongki, Kim Ki-Hyun, Deep Akash
Department of Nanotechnology, Sri Guru Granth Sahib World University, Fatehgarh Sahib, Punjab, 140406, India.
Department of Chemistry, Mata Gujri College, Fatehgarh Sahib, Punjab, 140406, India.
Biosens Bioelectron. 2021 Feb 1;173:112787. doi: 10.1016/j.bios.2020.112787. Epub 2020 Nov 6.
The quest for advanced management tools or options of various cancers has been on the rise to efficiently reduce their risks of mortality without the demerits of conventional treatments (e.g., undesirable side effects of the medications on non-target tissues, non-targeted distribution, slow clearance of the administered drugs, and the development of drug resistance over the duration of therapy). In this context, nanomaterials-antibody conjugates can offer numerous advantages in the development of cancer theranostics over conventional delivery systems (e.g., highly specific and enhanced biodistribution of the drug in targeted tissues, prolonged systemic circulation, low toxicity, and minimally invasive molecular imaging). This review comprehensively discusses and evaluates recent advances in the application of nanomaterial-antibody bioconjugates for cancer theranostics for the further advancement in the control of diverse cancerous diseases. Further, discussion is expanded to cover the various challenges and limitations associated with the design and development of nanomaterial-antibody conjugates applicable towards better management of cancer.
为了有效降低各种癌症的死亡风险，同时避免传统治疗方法的缺点（例如，药物对非靶组织产生不良副作用、非靶向分布、给药药物清除缓慢以及在治疗过程中产生耐药性），人们对先进的癌症管理工具或方案的探索一直在增加。在这种背景下，与传统递送系统相比，纳米材料-抗体缀合物在癌症诊疗学的发展中可提供众多优势（例如，药物在靶组织中的高度特异性和增强的生物分布、延长的全身循环、低毒性以及微创分子成像）。本综述全面讨论并评估了纳米材料-抗体生物缀合物在癌症诊疗学应用中的最新进展，以期在控制各种癌症疾病方面取得进一步进展。此外，讨论范围还扩大到涵盖与适用于更好管理癌症的纳米材料-抗体缀合物的设计和开发相关的各种挑战和限制。
